Press release – For immediate release – Thursday 6 April – 5:45 pm CEST
Median Technologies, the Imaging Phenomics Company™, and inVentiv Health, a leading biopharmaceutical professional services company, today announced a strategic alliance to offer biopharmaceutical clients with best-in-class medical image analysis and management services for early to late stage oncology clinical trials. The alliance will provide inVentiv clients with the most advanced imaging biomarkers, at a time when 73 percent of cancer compounds in clinical trials involve biomarkers in their research and development design.
Median, a leading services provider for image interpretation and management in oncology trials, will complement inVentiv Health’s comprehensive oncology solutions. inVentiv has extensive oncology experience and has worked with clients to develop and commercialize more than 78 percent of oncology products approved by the FDA and 84 percent of oncology drugs approved by the EMA in a recent five year period. This expertise provides inVentiv with a deep understanding about unique patient populations, study design challenges and special endpoints associated with oncology trials.
“We are very enthusiastic about this alliance. The services and expertise offered by inVentiv and Median are highly complementary – together we aim to leverage our expertise to help biopharmaceutical companies around the world make quicker, better informed decisions to bring new therapies to market. Within the field of oncology, imaging biomarkers provide a critical indication of patient response to therapy and thus are at the core of innovative therapy development. We are proud to bring our imaging expertise to inVentiv to help find better cures for cancer patients in need,” said Jeanne Hecht, COO of Median.
For early stage studies, Median will provide inVentiv clients with integrated imaging services to maximize access to meaningful and appropriate imaging biomarkers. This automated, standardized image management and endpoint review ensures clients receive easy access to the highest quality data to make fast, informed decisions. For late stage studies, Median provides core technology that has been cleared by the FDA and other regulatory bodies, providing high data integrity, reliability and transparency.
“Our relationship with Median Technologies provides inVentiv with access to industry leading imaging technology as we work with clients across the drug development phases,” said Anne Pilling, SVP, Global Project Management of inVentiv Health. “This is an example of our commitment to deploying smarter systems to support our biopharmaceutical partners accelerate the delivery of breakthrough oncology treatments to patients.”
inVentiv and Median will also provide advanced solutions that enhance the value of client services through the development of customer account technology, and the availability of Median’s Imaging Phenomics platform iBiopsy®, a cutting-edge imaging platform paving the way to predictive medicine through the analysis of imaging phenotypes.
Representatives from both organizations will be available to discuss the alliance in greater detail at the Annual ASCO Meeting, June 2-6 in Chicago.